RNA5SP183: A Potential Drug Target and Biomarker (G100873445)

Target Name: RNA5SP183

NCBI ID: G100873445

RNA5SP183

Other Name(s): RN5S183 | RNA, 5S ribosomal pseudogene 183

RNA5SP183: A Potential Drug Target and Biomarker

Abstract:

RNA5SP183, a non-coding RNA molecule, has been identified as a potential drug target and biomarker. Its expression has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. RNA5SP183 has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of these diseases. Further research is needed to understand its potential as a drug target and biomarker.

Introduction:

RNA5SP183 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an attractive target for researchers to investigate. RNA5SP183 has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Expression of RNA5SP183:

RNA5SP183 is a non-coding RNA molecule that is expressed in various tissues and cells. It has been shown to be expressed in tissues such as the brain, heart, and liver, and has been linked to the development and progression of various diseases. RNA5SP183 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and interacting with proteins such as RNA-protein interaction factors and transcription factors.

Role in Disease Development:

RNA5SP183 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Studies have shown that RNA5SP183 can promote the growth and survival of cancer cells and contribute to their metastasis. RNA5SP183 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by regulating the expression of genes involved in neurotransmission and cell survival.

RNA5SP183 has also been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, by regulating the expression of genes involved in immune response and inflammation.

Potential as a Drug Target:

RNA5SP183 has been shown to be a potential drug target by its ability to interact with proteins and to regulate the expression of genes involved in cell survival and disease development. Further research is needed to understand its specific mechanisms of action and to determine its potential as a drug target.

Potential as a Biomarker:

RNA5SP183 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Studies have shown that the expression of RNA5SP183 is associated with the development and progression of these diseases. Further research is needed to determine the accuracy and reliability of RNA5SP183 as a biomarker and to develop new diagnostic tests based on its expression.

Conclusion:

RNA5SP183 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an attractive target for researchers to investigate. Further research is needed to understand its potential as a drug target and biomarker, including its specific mechanisms of action and to determine its potential as a diagnostic tool.

Protein Name: RNA, 5S Ribosomal Pseudogene 183

The "RNA5SP183 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP183 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets